The 20-F confirms the core pharmaceutical business is shrinking while the company pivots to AI/insurance via massively dilutive stock-for-asset deals. The subsequent $12M private placement at $0.06 adds further overhang. Monitor for a reverse stock split to regain Nasdaq compliance before the October 21, 2026 deadline. The warrants from the private placement (200M shares exercisable at $0.12 and $0.15) represent additional future dilution risk.
Price Chart
Executive Summary
BGM Group Ltd.'s FY2025 20-F reveals a deeply deteriorating financial picture: net loss widened to $20.2M from $1.5M, driven by $10.2M in stock-based compensation and a $5.7M fair-value loss on trading securities. While total revenue grew 51% to $37.9M, this was entirely from newly acquired AI and insurance segments — the core pharmaceutical business declined 6% to $23.6M. Massive share issuance for stock-for-asset acquisitions during FY2025 (over 172M Class A shares) and a subsequent $12M private placement at $0.06 per share (200M new shares plus warrants for 200M more) have severely diluted existing holders. The company also faces Nasdaq delisting risk from a bid-price deficiency.
Key Facts
- Net loss attributable to shareholders widened to $19.94M in FY2025 from $1.44M in FY2024, a 1,282% increase
- Core pharmaceutical & allied products revenue declined 6% to $23.59M, while AI Solutions ($3.36M) and Insurance Business ($10.96M) were added via acquisitions
- Operating expenses surged 304% to $18.89M, including ~$10.23M in stock-based compensation from the 2025 equity incentive plan
- Other expense of $7.44M included a $5.65M loss from fair value change in trading securities
- Share count ballooned from ~200.6M shares at Sep 30, 2025 to over 400M after the June 2026 private placement of 200M Class A shares at $0.06
- Nasdaq issued a deficiency letter on April 24, 2026 for bid price below $1.00; compliance period ends October 21, 2026
- Cash and cash equivalents stood at $9.82M as of Sep 30, 2025, with total current assets of $51.55M and total current liabilities of $41.60M
Financial Impact
Net loss of $19.94M on $37.92M revenue; core pharma segment declining; massive dilution from 200M+ shares issued in FY2025 acquisitions and subsequent $12M private placement
Risk Factors
- Nasdaq delisting if bid price remains below $1.00 beyond October 21, 2026
- Massive dilution from 200M shares issued in June 2026 private placement and potential exercise of 200M warrants
- Declining core pharmaceutical revenue and gross margin compression (11% vs 16% prior year)
- PRC regulatory risks including VIE structure uncertainty and CSRC filing requirements
- Going-concern risk if cash burn continues — operating cash flow was negative $2.37M in FY2025
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 14 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 20-F Filing (Primary) | 0001104659-26-085247 |
| Document: bgm-20250930xex8d1.htm | 0001104659-26-085247 |
| Document: bgm-20250930xex12d3.htm | 0001104659-26-085247 |
| Document: bgm-20250930xex12d1.htm | 0001104659-26-085247 |
| Document: bgm-20250930xex12d2.htm | 0001104659-26-085247 |
| Document: bgm-20250930xex15d3.htm | 0001104659-26-085247 |
| Document: bgm-20250930xex15d2.htm | 0001104659-26-085247 |
| Document: bgm-20250930xex13d3.htm | 0001104659-26-085247 |
| Document: bgm-20250930xex13d2.htm | 0001104659-26-085247 |
| Document: bgm-20250930xex13d1.htm | 0001104659-26-085247 |
| Document: bgm-20250930xex15d1.htm | 0001104659-26-085247 |
| Document: 0001104659-26-085247-index-headers.html | 0001104659-26-085247 |
| Document: 0001104659-26-085247-index.html | 0001104659-26-085247 |
| Document: 0001104659-26-085247.txt | 0001104659-26-085247 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Aug 28, 2026 5w ago | 6-K | $0.3275 $0.2440 | ▲ +25.50% | ▲ +25.76% | $9.34 (−2751.91%) |
Jul 21, 2026 10w ago | 20-F | $0.3000 $0.2880 | ▲ +4.00% | ▲ +6.56% | $9.34 (−3013.33%) |
Jun 9, 2026 16w ago | 6-K | $0.3401 $0.3332 | ▲ +2.03% | ▲ +3.48% | $9.34 (−2646.25%) |
May 18, 2026 19w ago | 6-K | $0.2750 $0.4441 | ▼ −61.49% | ▼ −59.91% | $9.34 (−3296.36%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access